文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克血浆置换的临床与生化终点及反应预测因素:一项随机对照试验结果

Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial.
PubMed 文献 · Crit Care · 2022-05-12
一句话结论脓毒性休克辅助性血浆置换可持续降低去甲肾上腺素剂量并改善乳酸及生物标志物,基线乳酸水平可能预测反应。

本报告基于一项随机对照试验,纳入脓毒性休克持续时间<24小时且去甲肾上腺素需求≥0.4 μg/kg/min的患者,比较标准治疗(SOC)与SOC+单次治疗性血浆置换(TPE)。结果显示TPE组初始24小时内去甲肾上腺素剂量持续下降(SOC组估计每小时降低0.005 µg/kg/min,TPE组每小时降低0.018 µg/kg/min,p=0.004),乳酸水平在TPE组持续下降而SOC组上升(p=0.001)。TPE组多种生物标志物和疾病介质下降,保护性因子得到补充。多变量混合效应模型显示基线乳酸水平越高,TPE带来的去甲肾上腺素减量效应越大(p=0.004)。作者认为基线乳酸浓度可能作为反应预测因素指导未来大型RCT设计。

要点

  • 脓毒性休克<24小时且NE≥0.4 μg/kg/min患者,单次TPE使初始24小时NE剂量持续下降(SOC组每小时0.005 µg/kg/min vs TPE组每小时0.018 µg/kg/min,p=0.004)。
  • TPE组初始24小时乳酸水平持续下降,而SOC组乳酸水平上升(p=0.001)。
  • TPE组PCT(p=0.037)、vWF:Ag(p<0.001)、Angpt-2(p=0.009)、sTie-2(p=0.005)下降,AT-III(p=0.026)、Protein C(p=0.012)、ADAMTS-13(p=0.008)得到补充,SOC组未见。
  • 多变量混合效应模型显示基线乳酸水平升高与TPE带来的更大NE减量效应相关(p=0.004)。
  • 作者认为基线乳酸浓度可能作为TPE反应预测因素,指导未来大型RCT设计以评估硬终点。

适用人群与场景

  • 脓毒性休克持续时间<24小时且去甲肾上腺素需求≥0.4 μg/kg/min的患者。

处置流程与药物剂量

  • 标准治疗(SOC)或标准治疗+单次治疗性血浆置换(TPE)。

研究设计与关键结果

  • 研究类型:随机对照试验(RCT)的事后分析;样本量、中心数原文未报告。
  • 干预与对照:SOC vs SOC+单次TPE。
  • 主要终点结果:初始24小时NE剂量下降速率SOC组估计每小时0.005 µg/kg/min vs TPE组每小时0.018 µg/kg/min,p=0.004。
  • 关键次要终点:TPE组乳酸水平初始24小时持续下降而SOC组上升(p=0.001);TPE组PCT(p=0.037)、vWF:Ag(p<0.001)、Angpt-2(p=0.009)、sTie-2(p=0.005)下降,AT-III(p=0.026)、Protein C(p=0.012)、ADAMTS-13(p=0.008)补充,SOC组未见。
  • 多变量混合效应模型:基线乳酸水平升高与TPE相比SOC更大的NE减量效应相关(p=0.004)。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为基线乳酸浓度可能作为TPE反应预测因素,指导未来设计大型RCT以评估硬终点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock. Prediction of clinical efficacy in specific sepsis treatments is fundamental for individualized sepsis therapy.

METHODS: In the original RCT, patients with septic shock of < 24 h duration and norepinephrine (NE) requirement ≥ 0.4 μg/kg/min received standard of care (SOC) or SOC + one single TPE. Here, we report all clinical and biological endpoints of this study. Multivariate mixed-effects modeling of NE reduction was performed to investigate characteristics that could be associated with clinical response to TPE.

RESULTS: A continuous effect of TPE on the reduction in NE doses over the initial 24 h was observed (SOC group: estimated NE dose reduction of 0.005 µg/kg/min per hour; TPE group: 0.018 µg/kg/min per hour, p = 0.004). Similarly, under TPE, serum lactate levels, continuously decreased over the initial 24 h in the TPE group, whereas lactate levels increased under SOC (p = 0.001). A reduction in biomarkers and disease mediators (such as PCT (p = 0.037), vWF:Ag (p < 0.001), Angpt-2 (p = 0.009), sTie-2 (p = 0.005)) along with a repletion of exhausted protective factors (such as AT-III (p = 0.026), Protein C (p = 0.012), ADAMTS-13 (p = 0.008)) could be observed in the TPE but not in the SOC group. In a multivariate mixed effects model, increasing baseline lactate levels led to greater NE dose reduction effects with TPE as opposed to SOC (p = 0.004).

CONCLUSIONS: Adjunctive TPE is associated with the removal of injurious mediators and repletion of consumed protective factors altogether leading to preserved hemodynamic stabilization in refractory septic shock. We identified that baseline lactate concentration as a potential response predictor might guide future designing of large RCTs that will further evaluate TPE with regard to hard endpoints. Trial registration Retrospectively registered 18th January 2020 at clinicaltrials.gov (Identifier: NCT04231994 ).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Stahl K, Wand P, Seeliger B, et al. Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. Crit Care. 2022. PMID: 35551628. doi:10.1186/s13054-022-04003-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。